For Immediate Release
Bristol-Myers Squibb Supports HarborPath to Help Uninsured Individuals Living with HIV/AIDS Access Prescription Medicines
− HarborPath’s Partners Now Include Bristol-Myers Squibb, Gilead Sciences, Merck and ViiV Healthcare –
Columbia, SC - October 1, 2013
HarborPath, an organization which provides a single point of access to HIV/AIDS medications through patient assistance programs, welcomes Bristol-Myers Squibb as a participating company. Bristol-Myers Squibb, which is donating HIV/AIDS medications and funding, is the latest pharmaceutical company to support HarborPath since its formation in July 2012.
“The support of Bristol-Myers Squibb brings us one step closer to offering uninsured individuals living with HIV/AIDS access to their full regimen of medications through patient assistance programs,” said Ken Trogdon, Jr., President of HarborPath. “Access to life-saving medications is vital to individuals living with HIV, and these programs are invaluable to individuals who cannot afford their medications. We are thankful for the support of our pharmaceutical company partners, and we encourage others to join our efforts to streamline the application and medication fulfillment process to provide medications quickly to those who need them most.”
HarborPath is currently working with clinics in seven states and Washington, D.C. to help healthcare professionals and case managers connect individuals living with HIV/AIDS to multiple patient assistance programs using the application form on the HarborPath website. As of May 2013, HarborPath began administering the AIDS Drug Assistance Program (ADAP) Waiting List Program. Medications donated by AbbVie, Bristol-Myers Squibb, Gilead, Johnson & Johnson, Merck and ViiV Healthcare are dispensed to individuals who are on ADAP Waiting Lists through the HarborPath mail-order pharmacy.
“For the last 20 years, Bristol-Myers Squibb has worked collaboratively with HIV/AIDS community to help meet the diverse needs of patients living with this disease – from developing medicines to supporting disease education efforts to ongoing clinical research,” said Kabir Nath, Senior Vice-President, U.S. Virology, Bristol-Myers Squibb. “We are committed to helping ensure HIV patients have access to treatments now and in the future. Our partnership with HarborPath allows us to extend the reach of our patient assistance programs and help more individuals have access to therapy.”
HarborPath is a 501(c) (3) organization whose mission is to provide streamlined access to HIV/AIDS medications through patient assistance programs via an online portal. For more information, visit www.harborpath.org.
Sam Brown Inc. PR for HarborPath
Ken Trogdon, Jr.